Furthermore, EZH2 has been identified to be a promising tumor biomarker (Cai et al., 2011), and it represents a prognostic biomarker associated with immunosuppression in esophageal squamous carcinoma and hepatocellular carcinoma (Liu et al., 2016; Guo et al., 2020). Here, EZH2 is linked to neoplasm.